Zacks Investment Research Downgrades Aratana Therapeutics (PETX) to Hold

Aratana Therapeutics (NASDAQ:PETX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “

Several other brokerages also recently commented on PETX. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 15th. BidaskClub downgraded Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 2nd. Finally, Stifel Nicolaus cut their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, August 6th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $7.96.

Shares of Aratana Therapeutics stock opened at $5.76 on Tuesday. The firm has a market capitalization of $278.40 million, a price-to-earnings ratio of -5.94 and a beta of 2.37. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.44 and a current ratio of 3.02. Aratana Therapeutics has a 52 week low of $3.67 and a 52 week high of $7.28.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. The company had revenue of $4.91 million for the quarter, compared to the consensus estimate of $4.72 million. Aratana Therapeutics had a negative return on equity of 35.25% and a negative net margin of 154.23%. On average, equities analysts expect that Aratana Therapeutics will post -0.48 EPS for the current fiscal year.

In other Aratana Therapeutics news, insider Ernst Heinen sold 10,372 shares of the company’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $5.15, for a total value of $53,415.80. Following the transaction, the insider now owns 157,406 shares of the company’s stock, valued at approximately $810,640.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Steven St sold 75,000 shares of the stock in a transaction on Friday, September 21st. The stock was sold at an average price of $6.06, for a total value of $454,500.00. Following the transaction, the chief executive officer now directly owns 574,233 shares in the company, valued at approximately $3,479,851.98. The disclosure for this sale can be found here. Insiders sold a total of 104,187 shares of company stock worth $595,372 in the last ninety days. 5.30% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Northern Trust Corp grew its position in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock worth $2,082,000 after buying an additional 32,773 shares in the last quarter. Engaged Capital LLC grew its position in shares of Aratana Therapeutics by 20.0% during the 2nd quarter. Engaged Capital LLC now owns 2,400,000 shares of the biopharmaceutical company’s stock worth $10,200,000 after buying an additional 400,000 shares in the last quarter. Grandeur Peak Global Advisors LLC grew its position in shares of Aratana Therapeutics by 29.4% during the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 712,138 shares of the biopharmaceutical company’s stock worth $3,027,000 after buying an additional 161,675 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Aratana Therapeutics by 16.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 910,328 shares of the biopharmaceutical company’s stock worth $3,869,000 after buying an additional 125,232 shares in the last quarter. Finally, BlackRock Inc. grew its position in shares of Aratana Therapeutics by 11.5% during the 2nd quarter. BlackRock Inc. now owns 3,348,240 shares of the biopharmaceutical company’s stock worth $14,231,000 after buying an additional 345,204 shares in the last quarter. 65.44% of the stock is currently owned by institutional investors and hedge funds.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Further Reading: Call Option

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply